Soothing the inflamed brain: Effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 1, 2011, Pages 57-67

  Hoozemans, J J M ^a   Veerhuis, R ^a,b   Rozemuller, J M ^a   Eikelenboom, P ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

amyloid; Alzheimer's disease; Cyclooxygenase; Inflammation; Microglia; Non steroidal anti inflammatory drugs

Indexed keywords

AMYLOID BETA PROTEIN; CELECOXIB; CLUSTERIN; COMPLEMENT COMPONENT C3B RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOOXYGENASE 1 INHIBITOR; DICLOFENAC; FLURBIPROFEN; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; SULINDAC; TAU PROTEIN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CLINICAL FEATURE; DRUG TARGETING; ENCEPHALITIS; GENOME ANALYSIS; HUMAN; MICROGLIA; NONHUMAN; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT; ANIMAL; BRAIN; DISEASE COURSE; DRUG EFFECT; GENETIC ASSOCIATION; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; DISEASE PROGRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MICROGLIA; MOLECULAR TARGETED THERAPY;

EID: 79960997729     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711794488665     Document Type: Review

References (126)

1. Eikelenboom, P.; Veerhuis, R.; Scheper, W.; Rozemuller, A.J.; van Gool, W.A.; Hoozemans, J.J. The significance of neuroinflammation in understanding Alzheimer's disease. J. Neural Transm., 2006, 113, 1685-1695.
2. Alzheimer, A. Uber eine eigenartige Erkrankung der Hirnrinde. Algemeine Zeitschrift Psych. Psychisch-Gerichtliche Med., 1907, 64, 146-148.
3. Nelson, P.T.; Braak, H.; Markesbery, W.R. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J. Neuropathol. Exp. Neurol., 2009, 68, 1-14.
4. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci., 1991, 12, 383-388.
5. Selkoe, D.J. Amyloid protein and Alzheimer's disease. Sci. Am., 1991, 265, 68-71.
6. Selkoe, D.J. Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. Curr. Opin. Neurobiol., 1994, 4, 708-716.
7. Marr, R.A.; Spencer, B.J. NEP-like Endopeptidases and Alzheimer's Disease. Curr. Alzheimer Res., 2010, 7(10), 223-229.
8. Theuns, J.; Brouwers, N.; Engelborghs, S.; Sleegers, K.; Bogaerts, V.; Corsmit, E.; De Pooter, T.; van Duijn, C.M.; De Deyn, P.P.; Van Broeckhoven, C. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am. J. Hum. Genet., 2006, 78, 936-946.
9. Strittmatter, W.J.; Saunders, A.M.; Schmechel, D.; Pericak-Vance, M.; Enghild, J.; Salvesen, G.S.; Roses, A.D. Apolipoprotein E: high-avidity binding to betaβamyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1993, 90, 1977-1981.
10. Donahue, J.E.; Johanson, C.E. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2008, 67, 261-270.
11. Poirier, J. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann. NY Acad. Sci., 2000, 924, 81-90.
12. Rozemuller, J.M.; Eikelenboom, P.; Stam, F.C.; Beyreuther, K.; Masters, C.L. A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition. J. Neuropathol. Exp. Neurol., 1989, 48, 674-691
13. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; O'Banion, M.K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimer's disease. Neurobiol. Aging, 2000, 21, 383-421.
14. Eikelenboom, P.; van Gool, W.A. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J. Neural Transm., 2004, 111, 281-294.
15. Nielsen, H.M.; Veerhuis, R.; Holmqvist, B.; Janciauskiene, S. Binding and uptake of A beta1-42 by primary human astrocytes in vitro. Glia, 2009, 57, 978-988.
16. Suzuki, N.; Saito, T. IRAK-4--a shared NF-kappaB activator in innate and acquired immunity. Trends Immunol., 2006, 27, 566-572.
17. Hauss-Wegrzyniak, B.; Dobrzanski, P.; Stoehr, J.D.; Wenk, G.L. Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain. Res., 1998, 780, 294-303.
18. Fassbender, K.; Walter, S.; Kuhl, S.; Landmann, R.; Ishii, K.; Bertsch, T.; Stalder, A.K.; Muehlhauser, F.; Liu, Y.; Ulmer, A.J.; Rivest, S.; Lentschat, A.; Gulbins, E.; Jucker, M.; Staufenbiel, M.; Brechtel, K.; Walter, J.; Multhaup, G.; Penke, B.; Adachi, Y.; Hartmann, T.; Beyreuther, K. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J., 2004, 18, 203-205.
19. Udan, M.L.; Ajit, D.; Crouse, N.R.; Nichols, M.R. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J. Neurochem., 2008, 104, 524-533.
20. Tahara, K.; Kim, H.D.; Jin, J.J.; Maxwell, J.A.; Li, L.; Fukuchi, K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain, 2006, 129, 3006-3019.
21. Eikelenboom, P.; van Gool, W.A. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J. Neural Transm., 2004, 111, 281-294.
22. Suzuki, N.; Suzuki, S.; Yeh, W.C. IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol., 2002, 23, 503-506.
23. Griffin, W.S.; Sheng, J.G.; Roberts, G.W.; Mrak, R.E. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol., 1995, 54, 276-281.
24. Shaftel, S.S.; Griffin, W.S.; O'Banion, M.K. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J. Neuroinflammation, 2008, 5, 7.
25. Mrak, R.E.; Griffin, W.S. Trisomy 21 and the brain. J. Neuropathol. Exp. Neurol., 2004, 63, 679-685.
26. McGeer, P.L.; McGeer, E.G. Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch. Neurol., 2001, 58, 1790-1792.
27. Hoozemans, J.J.; Veerhuis, R.; Janssen, I.; van Elk, E.J.; Rozemuller, A.J.; Eikelenboom, P. The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer's disease. Brain Res., 2002, 951, 218-226.
28. Blom, M.A.; vanTwillert, M.G.; de Vries, S.C.; Engels, F.; Finch, C.E.; Veerhuis, R.; Eikelenboom, P. NSAIDS inhibit the IL-1 betainduced IL-6 release from human post-mortem astrocytes: the involvement of prostaglandin E2. Brain Res., 1997, 777, 210-218.
29. Lieb, K.; Kaltschmidt, C.; Kaltschmidt, B.; Baeuerle, P.A.; Berger, M.; Bauer, J.; Fiebich, B.L. Interleukin-1 beta uses common and distinct signaling pathways for induction of the interleukin-6 and tumor necrosis factor alpha genes in the human astrocytoma cell line U373. J. Neurochem., 1996, 66, 1496-1503.
30. Fiebich, B.L.; Lieb, K.; Hull, M.; Berger, M.; Bauer, J. Effects of NSAIDs on IL-1 beta-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Neuroreport, 1996, 7, 1209-1213.
31. Hoozemans, J.J.; Veerhuis, R.; Rozemuller, A.J.; Eikelenboom, P. The pathological cascade of Alzheimer's disease: the role of inflammation and its therapeutic implications. Drugs Today (Barc.), 2002, 38, 429-443.
32. Griffin, W.S.; Sheng, J.G.; Royston, M.C.; Gentleman, S.M.; McKenzie, J.E.; Graham, D.I.; Roberts, G.W.; Mrak, R.E. Glialneuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol., 1998, 8, 65-72.
33. Barger, S.W.; Harmon, A.D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature, 1997, 388, 878-881.
34. Rogers, J.T.; Leiter, L.M.; McPhee, J.; Cahill, C.M.; Zhan, S.S.; Potter, H.; Nilsson, L.N. Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. J. Biol. Chem., 1999, 274, 6421-6431.
35. Sheng, J.G.; Ito, K.; Skinner, R.D.; Mrak, R.E.; Rovnaghi, C.R.; Van Eldik, L.J.; Griffin, W.S. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol. Aging, 1996, 17, 761-766.
36. Sheng, J.G.; Zhu, S.G.; Jones, R.A.; Griffin, W.S.; Mrak, R.E. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp. Neurol., 2000, 163, 388-391.
37. Harold, D.; Abraham, R.; Hollingworth, P.; Sims, R.; Gerrish, A.; Hamshere, M.L.; Pahwa, J.S.; Moskvina, V.; Dowzell, K.; Williams, A.; Jones, N.; Thomas, C.; Stretton, A.; Morgan, A.R.; Lovestone, S.; Powell, J.; Proitsi, P.; Lupton, M.K.; Brayne, C.; Rubinsztein, D.C.; Gill, M.; Lawlor, B.; Lynch, A.; Morgan, K.; Brown, K.S.; Passmore, P.A.; Craig, D.; McGuinness, B.; Todd, S.; Holmes, C.; Mann, D.; Smith, A.D.; Love, S.; Kehoe, P.G.; Hardy, J.; Mead, S.; Fox, N.; Rossor, M.; Collinge, J.; Maier, W.; Jessen, F.; Schurmann, B.; van den, B.H.; Heuser, I.; Kornhuber, J.; Wiltfang, J.; Dichgans, M.; Frolich, L.; Hampel, H.; Hull, M.; Rujescu, D.; Goate, A.M.; Kauwe, J.S.; Cruchaga, C.; Nowotny, P.; Morris, J.C.; Mayo, K.; Sleegers, K.; Bettens, K.; Engelborghs, S.; De Deyn, P.P.; Van Broeckhoven, C.; Livingston, G.; Bass, N.J.; Gurling, H.; McQuillin, A.; Gwilliam, R.; Deloukas, P.; Al Chalabi, A.; Shaw, C.E.; Tsolaki, M.; Singleton, A.B.; Guerreiro, R.; Muhleisen, T.W.; Nothen, M.M.; Moebus, S.; Jockel, K.H.; Klopp, N.; Wichmann, H.E.; Carrasquillo, M.M.; Pankratz, V.S.; Younkin, S.G.; Holmans, P.A.; O'Donovan, M.; Owen, M.J.; Williams, J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet., 2009, 41, 1088-1093.
38. Lambert, J.C.; Heath, S.; Even, G.; Campion, D.; Sleegers, K.; Hiltunen, M.; Combarros, O.; Zelenika, D.; Bullido, M.J.; Tavernier, B.; Letenneur, L.; Bettens, K.; Berr, C.; Pasquier, F.; Fievet, N.; Barberger-Gateau, P.; Engelborghs, S.; De Deyn, P.; Mateo, I.; Franck, A.; Helisalmi, S.; Porcellini, E.; Hanon, O.; de Pancorbo, M.M.; Lendon, C.; Dufouil, C.; Jaillard, C.; Leveillard, T.; Alvarez, V.; Bosco, P.; Mancuso, M.; Panza, F.; Nacmias, B.; Bossu, P.; Piccardi, P.; Annoni, G.; Seripa, D.; Galimberti, D.; Hannequin, D.; Licastro, F.; Soininen, H.; Ritchie, K.; Blanche, H.; Dartigues, J.F.; Tzourio, C.; Gut, I.; Van Broeckhoven, C.; Alperovitch, A.; Lathrop, M.; Amouyel, P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet., 2009, 41, 1094-1099.
39. van Exel, E.; Eikelenboom, P.; Comijs, H.; Frolich, M.; Smit, J.H.; Stek, M.L.; Scheltens, P.; Eefsting, J.E.; Westendorp, R.G. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch. Gen. Psychiatry, 2009, 66, 1263-1270.
40. de Craen, A.J.; Posthuma, D.; Remarque, E.J.; van den Biggelaar, A.H.; Westendorp, R.G.; Boomsma, D.I. Heritability estimates of innate immunity: an extended twin study. Genes Immun., 2005, 6, 167-170.
41. Arends, Y.M.; Duyckaerts, C.; Rozemuller, J.M.; Eikelenboom, P.; Hauw, J.J. Microglia, amyloid and dementia in alzheimer disease. A correlative study. Neurobiol. Aging, 2000, 21, 39-47.
42. Hoozemans, J.J.; Van Haastert, E.S.; Veerhuis, R.; Arendt, T.; Scheper, W.; Eikelenboom, P.; Rozemuller, A.J. Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. J. Neuroinflamm., 2005, 2, 27.
43. Cagnin, A.; Brooks, D.J.; Kennedy, A.M.; Gunn, R.N.; Myers, R.; Turkheimer, F.E.; Jones, T.; Banati, R.B. In-vivo measurement of activated microglia in dementia. Lancet, 2001, 358, 461-467
44. Veerhuis, R.; Van Breemen, M.J.; Hoozemans, J.M.; Morbin, M.; Ouladhadj, J.; Tagliavini, F.; Eikelenboom, P. Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol. (Berl.), 2003, 105, 135-144.
45. Blalock, E.M.; Geddes, J.W.; Chen, K.C.; Porter, N.M.; Markesbery, W.R.; Landfield, P.W. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. USA, 2004, 101, 2173-2178.
46. Jenkinson, M.L.; Bliss, M.R.; Brain, A.T.; Scott, D.L. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br. J. Rheumatol., 1989, 28, 86-88.
47. Breitner, J.C.; Gau, B.A.; Welsh, K.A.; Plassman, B.L.; McDonald, W.M.; Helms, M.J.; Anthony, J.C. Inverse association of antiinflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology, 1994, 44, 227-232.
48. McGeer, P.L.; Schulzer, M.; McGeer, E.G. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology, 1996, 47, 425-432.
49. in t' Veld, B.A.; Ruitenberg, A.; Hofman, A.; Launer, L.J.; van Duijn, C.M.; Stijnen, T.; Breteler, M.M.; Stricker, B.H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med., 2001, 345, 1515-1521.
50. Rogers, J.; Kirby, L.C.; Hempelman, S.R.; Berry, D.L.; McGeer, P.L.; Kaszniak, A.W.; Zalinski, J.; Cofield, M.; Mansukhani, L.; Willson, P. Clinical trial of indomethacin in Alzheimer's disease. Neurology, 1993, 43, 1609-1611.
51. Scharf, S.; Mander, A.; Ugoni, A.; Vajda, F.; Christophidis, N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology, 1999, 53, 197-201.
52. Aisen, P.S.; Davis, K.L.; Berg, J.D.; Schafer, K.; Campbell, K.; Thomas, R.G.; Weiner, M.F.; Farlow, M.R.; Sano, M.; Grundman, M.; Thal, L.J. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology, 2000, 54, 588-593.
53. Aisen, P.S.; Schafer, K.A.; Grundman, M.; Pfeiffer, E.; Sano, M.; Davis, K.L.; Farlow, M.R.; Jin, S.; Thomas, R.G.; Thal, L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA, 2003, 289, 2819-2826.
54. van Gool, W.A.; Weinstein, H.C.; Scheltens, P.K.; Walstra, G.J. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo- controlled study. Lancet, 2001, 358, 455-460.
55. Reines, S.A.; Block, G.A.; Morris, J.C.; Liu, G.; Nessly, M.L.; Lines, C.R.; Norman, B.A.; Baranak, C.C. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology, 2004, 62, 66-71.
56. Aisen, P.S. Results of a multicenter trial of rofecoxib and naproxen in Alzheimer's disease. Neurobiol. Aging, 2002, 23, S429.
57. van Gool, W.A.; Aisen, P.S.; Eikelenboom, P. Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? J. Neurol., 2003, 250, 788-792.
58. Liano, C. In follow-up analysis of clinical trial, NSAIDs seem to preserve cognitive function in patients with healthy brains. Neurol. Today, 2009, 9, 21-22.
59. Martin, B.K.; Szekely, C.; Brandt, J.; Piantadosi, S.; Breitner, J.C.; Craft, S.; Evans, D.; Green, R.; Mullan, M. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol., 2008, 65, 896-905.
60. Breitner, J.C. Treatment Effects of NSAIDs Related to Stage of AD Pathogenesis - Lessons from ADAPT (abstract). Alzheimer's Association 2009 International Conference on Alzheimer's Disease. Vienna, Austria, 2009.
61. McGeer, P.L.; McGeer, E.G. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging, 2007, 28, 639-647.
62. Vane, J.R.; Botting, R.M. Mechanism of action of antiinflammatory drugs. Int. J. Tissue React., 1998, 20, 3-15.
63. Herschman, H.R. Prostaglandin synthase 2. Biochim. Biophys. Acta, 1996, 1299, 125-140.
64. Yamagata, K.; Andreasson, K.I.; Kaufmann, W.E.; Barnes, C.A.; Worley, P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron, 1993, 11, 371-386.
65. Breder, C.D.; Dewitt, D.; Kraig, R.P. Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol., 1995, 355, 296-315.
66. Yasojima, K.; Schwab, C.; McGeer, E.G.; McGeer, P.L. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res., 1999, 830, 226-236.
67. O'Banion, M.K. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit. Rev. Neurobiol., 1999, 13, 45-82.
68. Chen, C.; Magee, J.C.; Bazan, N.G. Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity. J. Neurophysiol., 2002, 87, 2851-2857.
69. Kaufmann, W.E.; Worley, P.F.; Pegg, J.; Bremer, M.; Isakson, P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. USA, 1996, 93, 2317-2321.
70. Shaw, K.N.; Commins, S.; O'Mara, S.M. Deficits in spatial learning and synaptic plasticity induced by the rapid and competitive broad-spectrum cyclooxygenase inhibitor ibuprofen are reversed by increasing endogenous brain-derived neurotrophic factor. Eur. J. Neurosci., 2003, 17, 2438-2446.
71. Rall, J.M.; Mach, S.A.; Dash, P.K. Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats. Brain Res., 2003, 968, 273-276.
72. Yermakova, A.V.; Rollins, J.; Callahan, L.M.; Rogers, J.; O'Banion, M.K. Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J. Neuropathol. Exp. Neurol., 1999, 58, 1135-1146.
73. Hoozemans, J.J.; Rozemuller, A.J.; Janssen, I.; de Groot, C.J.; Veerhuis, R.; Eikelenboom, P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. (Berl.), 2001, 101, 2-8.
74. Fiebich, B.L.; Biber, K.; Lieb, K.; van Calker, D.; Berger, M.; Bauer, J.; Gebicke-Haerter, P.J. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia, 1996, 18, 152-160.
75. Minghetti, L.; Levi, G. Induction of prostanoid biosynthesis by bacterial lipopolysaccharide and isoproterenol in rat microglial cultures. J. Neurochem., 1995, 65, 2690-2698.
76. Bauer, M.K.; Lieb, K.; Schulze-Osthoff, K.; Berger, M.; Gebicke- Haerter, P.J.; Bauer, J.; Fiebich, B.L. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur. J. Biochem., 1997, 243, 726-731.
77. Tomimoto, H.; Akiguchi, I.; Wakita, H.; Lin, J.X.; Budka, H. Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans. Acta. Neuropathol. (Berl.), 2000, 99, 26-30.
78. Walsh, D.T.; Perry, V.H.; Minghetti, L. Cyclooxygenase-2 is highly expressed in microglial-like cells in a murine model of prion disease. Glia, 2000, 29, 392-396.
79. O'Banion, M.K.; Miller, J.C.; Chang, J.W.; Kaplan, M.D.; Coleman, P.D. Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase- 2) in primary murine astrocyte cultures. J. Neurochem., 1996, 66, 2532-2540.
80. Fiebich, B.L.; Hull, M.; Lieb, K.; Gyufko, K.; Berger, M.; Bauer, J. Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. J. Neurochem., 1997, 68, 704-709.
81. Fiebich, B.L.; Schleicher, S.; Spleiss, O.; Czygan, M.; Hull, M. Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C. J. Neurochem., 2001, 79, 950-958.
82. Yermakova, A.V.; O'Banion, M.K. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol. Aging, 2001, 22, 823-836.
83. Maslinska, D.; Wozniak, R.; Kaliszek, A.; Modelska, I. Expression of cyclooxygenase-2 in astrocytes of human brain after global ischemia. Folia Neuropathol., 1999, 37, 75-79.
84. Hoozemans, J.J.; Veerhuis, R.; Janssen, I.; Rozemuller, A.J.; Eikelenboom, P. Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. Exp. Gerontol., 2001, 36, 559-570.
85. Braak, H.; Braak, E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol. (Berl.), 1991, 82, 239-259.
86. Ho, L.; Purohit, D.; Haroutunian, V.; Luterman, J.D.; Willis, F.; Naslund, J.; Buxbaum, J.D.; Mohs, R.C.; Aisen, P.S.; Pasinetti, G.M. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch. Neurol., 2001, 58, 487-492.
87. Hoozemans, J.J.; Bruckner, M.K.; Rozemuller, A.J.; Veerhuis, R.; Eikelenboom, P.; Arendt, T. Cyclin D1 and cyclin E are colocalized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J. Neuropathol. Exp. Neurol., 2002, 61, 678-688.
88. Oka, A.; Takashima, S. Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport, 1997, 8, 1161-1164.
89. Hoozemans, J.J.; Veerhuis, R.; Rozemuller, A.J.; Arendt, T.; Eikelenboom, P. Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex. Neurobiol. Dis., 2004, 15, 492-499.
90. Minghetti, L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol., 2004, 63, 901-910.
91. Combrinck, M.; Williams, J.; De Berardinis, M.A.; Warden, D.; Puopolo, M.; Smith, A.D.; Minghetti, L. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 2006, 77, 85-88.
92. Mirjany, M.; Ho, L.; Pasinetti, G.M. Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J. Pharmacol. Exp. Ther., 2002, 301, 494-500.
93. Arendt, T.; Rodel, L.; Gartner, U.; Holzer, M. Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. Neuroreport, 1996, 7, 3047-3049.
94. Nagy, Z.; Esiri, M.M.; Cato, A.M.; Smith, A.D. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol. (Berl.), 1997, 94, 6-15.
95. Ranganathan, S.; Bowser, R. Alterations in G(1) to S phase cellcycle regulators during amyotrophic lateral sclerosis. Am. J. Pathol., 2003, 162, 823-835.
96. Vincent, I.; Jicha, G.; Rosado, M.; Dickson, D.W. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J. Neurosci., 1997, 17, 3588-3598.
97. Kranenburg, O.; van der Eb, A.J.; Zantema, A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J., 1996, 15, 46-54.
98. Copani, A.; Condorelli, F.; Caruso, A.; Vancheri, C.; Sala, A.; Giuffrida Stella, A.M.; Canonico, P.L.; Nicoletti, F.; Sortino, M.A. Mitotic signaling by betaβamyloid causes neuronal death. FASEB J., 1999, 13, 2225-2234.
99. Xiang, Z.; Ho, L.; Valdellon, J.; Borchelt, D.; Kelley, K.; Spielman, L.; Aisen, P.S.; Pasinetti, G.M. Cyclooxygenase (COX)- 2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol. Aging, 2002, 23, 327-334.
100. Wu Chen, R.; Zhang, Y.; Rose, M.E.; Graham, S.H. Cyclooxygenase-2 activity contributes to neuronal expression of cyclin D1 after anoxia/ischemia in vitro and in vivo. Brain Res. Mol. Brain Res., 2004, 132, 31-37.
101. Candelario-Jalil, E.; de Oliveira, A.C.; Graf, S.; Bhatia, H.S.; Hull, M.; Munoz, E.; Fiebich, B.L. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J. Neuroinflammation, 2007, 4, 25.
102. Stephenson, D.T.; Lemere, C.A.; Selkoe, D.J.; Clemens, J.A. Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol. Dis., 1996, 3, 51-63.
103. Stella, N.; Estelles, A.; Siciliano, J.; Tence, M.; Desagher, S.; Piomelli, D.; Glowinski, J.; Premont, J. Interleukin-1 enhances the ATP-evoked release of arachidonic acid from mouse astrocytes. J. Neurosci., 1997, 17, 2939-2946.
104. Choi, S.H.; Langenbach, R.; Bosetti, F. Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J., 2008, 22, 1491-1501.
105. Choi, S.H.; Bosetti, F. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to betaβamyloid. Aging, 2009, 1, 234-244.
106. Lim, G.P.; Yang, F.; Chu, T.; Chen, P.; Beech, W.; Teter, B.; Tran, T.; Ubeda, O.; Ashe, K.H.; Frautschy, S.A.; Cole, G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci., 2000, 20, 5709-5714.
107. Mackenzie, I.R.; Munoz, D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology, 1998, 50, 986-990.
108. Kitamura, Y.; Shimohama, S.; Koike, H.; Kakimura, J.; Matsuoka, Y.; Nomura, Y.; Gebicke-Haerter, P.J.; Taniguchi, T. Increased expression of cyclooxygenases and peroxisome proliferatoractivated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun., 1999, 254, 582-586.
109. Petrova, T.V.; Akama, K.T.; Van Eldik, L.J. Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14- prostaglandin J2. Proc. Natl. Acad. Sci. USA, 1999, 96, 4668-4673.
110. Bernardo, A.; Levi, G.; Minghetti, L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci., 2000, 12, 2215-2223.
111. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 1998, 391, 79-82.
112. Jiang, C.; Ting, A.T.; Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998, 391, 82-86.
113. Camacho, I.E.; Serneels, L.; Spittaels, K.; Merchiers, P.; Dominguez, D.; De Strooper, B. Peroxisome proliferator-activated receptor gamma induces a clearance mechanism for the amyloidbeta peptide. J. Neurosci., 2004, 24, 10908-10917.
114. Weggen, S.; Eriksen, J.L.; Das, P.; Sagi, S.A.; Wang, R.; Pietrzik, C.U.; Findlay, K.A.; Smith, T.E.; Murphy, M.P.; Bulter, T.; Kang, D.E.; Marquez-Sterling, N.; Golde, T.E.; Koo, E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 2001, 414, 212-216.
115. Eriksen, J.L.; Sagi, S.A.; Smith, T.E.; Weggen, S.; Das, P.; McLendon, D.C.; Ozols, V.V.; Jessing, K.W.; Zavitz, K.H.; Koo, E.H.; Golde, T.E. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest., 2003, 112, 440-449.
116. Morihara, T.; Chu, T.; Ubeda, O.; Beech, W.; Cole, G.M. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J. Neurochem., 2002, 83, 1009-1012.
117. Jantzen, P.T.; Connor, K.E.; DiCarlo, G.; Wenk, G.L.; Wallace, J.L.; Rojiani, A.M.; Coppola, D.; Morgan, D.; Gordon, M.N. Microglial activation and beta βamyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci., 2002, 22, 2246-2254.
118. Weggen, S.; Eriksen, J.L.; Sagi, S.A.; Pietrzik, C.U.; Ozols, V.; Fauq, A.; Golde, T.E.; Koo, E.H. Evidence that nonsteroidal antiinflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J. Biol. Chem., 2003, 278, 31831-31837.
119. Beher, D.; Clarke, E.E.; Wrigley, J.D.; Martin, A.C.; Nadin, A.; Churcher, I.; Shearman, M.S. Selected non-steroidal antiinflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem., 2004, 279, 43419-43426.
120. Lleo, A.; Berezovska, O.; Herl, L.; Raju, S.; Deng, A.; Bacskai, B.J.; Frosch, M.P.; Irizarry, M.; Hyman, B.T. Nonsteroidal antiinflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat. Med., 2004, 10, 1065-1066.
121. Gasparini, L.; Ongini, E.; Wenk, G. Non-steroidal antiinflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J. Neurochem., 2004, 91, 521-536.
122. Wyss-Coray, T.; Mucke, L. Inflammation in neurodegenerative disease--a double-edged sword. Neuron, 2002, 35, 419-432.
123. Hoozemans, J.J.; Veerhuis, R.; Rozemuller, A.J.; Eikelenboom, P. Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. Curr. Drug Targets, 2003, 4, 461-468.
124. Varvel, N.H.; Bhaskar, K.; Kounnas, M.Z.; Wagner, S.L.; Yang, Y.; Lamb, B.T.; Herrup, K. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J. Clin. Invest., 2009, 119, 3692-3702.
125. Wu, Q.; Combs, C.; Cannady, S.B.; Geldmacher, D.S.; Herrup, K. Betaβamyloid activated microglia induce cell cycling and cell death in cultured cortical neurons. Neurobiol. Aging, 2000, 21, 797-806.
126. Hoozemans, J.J.; Rozemuller, J.M.; Van Haastert, E.S.; Veerhuis, R.; Eikelenboom, P. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr. Pharm. Des., 2008, 14, 1419-1427.